MYRIAD GENETICS INC — Form 8-K
Filed October 20, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 58/100
What the filing says
Myriad Genetics is selling its women's health and prenatal testing business (SneakPeek, Foresight, Prequel, FirstGene tests) to Laboratory Corporation of America (LabCorp) for a base purchase price of $210 million plus inventory adjustments. The transaction includes transfer of intellectual property, regulatory permits, facilities at two California locations, employee offers, and transition services. Closing expected within 5-90 business days subject to regulatory approvals including HSR antitrust clearance.
Why this rating
Material divestiture (~$210M or ~43% of Myriad's $494M market cap) represents significant business restructuring; moderate relative to company size but ordinary M&A activity not transformational.
See more from October 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.